Covered recipient · General Payments record
BRANDICE A ROGERS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$2,952.47
- Reported across 157 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $669.85 | 32 |
| Education | $56.44 | 2 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $208.47 | 12 |
| Phathom Pharmaceuticals, Inc. | $122.83 | 1 |
| Janssen Biotech, Inc. | $85.33 | 3 |
| UCB, Inc. | $85.19 | 5 |
| Lilly USA, LLC | $65.72 | 4 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $57.15 | 3 |
| GENZYME CORPORATION | $30.61 | 2 |
| E.R. Squibb & Sons, L.L.C. | $25.43 | 1 |
| LEO Pharma Inc. | $16.58 | 1 |
| Amgen Inc. | $15.26 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $13.72 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (34)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202120222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $22.47 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105943 | CMS |
| ABBVIE INC. | $22.98 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105945 | CMS |
| ABBVIE INC. | $10.34 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105947 | CMS |
| ABBVIE INC. | $8.45 | 04/30/2024 | Education | Undisputed | 01/23/2026 | 1108105949 | CMS |
| ABBVIE INC. | $25.50 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105951 | CMS |
| ABBVIE INC. | $30.80 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105953 | CMS |
| ABBVIE INC. | $24.72 | 06/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105955 | CMS |
| ABBVIE INC. | $18.34 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105957 | CMS |
| ABBVIE INC. | $8.86 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105959 | CMS |
| ABBVIE INC. | $16.15 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105961 | CMS |
| ABBVIE INC. | $11.65 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105963 | CMS |
| ABBVIE INC. | $8.21 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108105965 | CMS |
| Amgen Inc. | $15.26 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117669057 | CMS |
| E.R. Squibb & Sons, L.L.C. | $25.43 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101270785 | CMS |
| GENZYME CORPORATION | $13.33 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139838493 | CMS |
| GENZYME CORPORATION | $17.28 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139838539 | CMS |
| Janssen Biotech, Inc. | $47.99 | 04/02/2024 | Education | Undisputed | 01/23/2026 | 1078270969 | CMS |
| Janssen Biotech, Inc. | $16.16 | 10/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078270967 | CMS |
| Janssen Biotech, Inc. | $21.18 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078270971 | CMS |
| LEO Pharma Inc. | $16.58 | 01/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152685747 | CMS |
| Lilly USA, LLC | $13.21 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135587383 | CMS |
| Lilly USA, LLC | $18.34 | 06/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135541583 | CMS |
| Lilly USA, LLC | $19.34 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135541581 | CMS |
| Lilly USA, LLC | $14.83 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135553109 | CMS |
| Novartis Pharmaceuticals Corporation | $13.72 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1087161417 | CMS |
| Phathom Pharmaceuticals, Inc. | $122.83 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151201387 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $16.03 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152221521 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $19.27 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152221523 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $21.85 | 12/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152221525 | CMS |
| UCB, Inc. | $13.46 | 03/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143380258 | CMS |
| UCB, Inc. | $17.38 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143380263 | CMS |
| UCB, Inc. | $16.19 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143380267 | CMS |
| UCB, Inc. | $17.80 | 08/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143380271 | CMS |
| UCB, Inc. | $20.36 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143380276 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.